Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’

Executive Summary

FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.

You may also be interested in...

No Vote, No Mandate? FDA Opioid Meeting Shows Limits Of Non-Voting Panels

US FDA Commissioner Califf has proposed that the agency move away from ‘gladiator votes’ that frame advisory committee meetings as a yes-or-no decision on a single question and instead emphasize the importance of the expert discussion and nuance of regulatory issues. The latest high-profile advisory committee review of a key opioid response issue shows the challenges with that approach.

Opioid Long-Term Effectiveness Trial Design Gets Middling Review From FDA Panel

Advisory committee agrees that a proposed study protocol could enroll patients but notes the outcome is foreseeable. Industry representative questions whether this postmarketing requirement is necessary.

CDC Advises Against Use Of Extended Release Opioids, Redefines High Dose

New clinical practice guideline recommends immediate-release opioids instead of extended-release and long-acting opioids when starting pain therapy. It specifies high dose is 50 mg morphine equivalent dose (MME) per day or higher. The 2016 guideline had set it at 90 MME/day.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts